{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:40:22Z","timestamp":1776836422115,"version":"3.51.2"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015329","name":"Amgen Inc San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jim.2025.113904","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:23:32Z","timestamp":1752679412000},"page":"113904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A high-throughput assay using dysfunctional T cells for phenotypic screening immune checkpoint modulators"],"prefix":"10.1016","volume":"542","author":[{"given":"Zhiyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William John","family":"Huth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwina","family":"Naik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaylee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2025.113904_bb0005","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2217\/imt.09.70","article-title":"Toll-like receptor agonists in cancer therapy","volume":"1","author":"Adams","year":"2009","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jim.2025.113904_bb0010","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0024-3205(96)00567-X","article-title":"Euphorbium: modern research on its active principle, resiniferatoxin, revives an ancient medicine","volume":"60","author":"Appendino","year":"1997","journal-title":"Life Sci."},{"key":"10.1016\/j.jim.2025.113904_bb0015","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jim.2025.113904_bb0020","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41586-023-06575-7","article-title":"The PTPN2\/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity","volume":"622","author":"Baumgartner","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jim.2025.113904_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.67","article-title":"Interferon-\u03b3 derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity","volume":"8","author":"Bhat","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jim.2025.113904_bb0030","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.036236","article-title":"Immune regulation of metastasis: mechanistic insights and therapeutic opportunities","volume":"11","author":"Blomberg","year":"2018","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.jim.2025.113904_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.608747","article-title":"Modulation of TCR signaling by tyrosine phosphatases: from autoimmunity to immunotherapy","volume":"8","author":"Castro-Sanchez","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jim.2025.113904_bb0040","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1158\/2326-6066.CIR-21-0806","article-title":"CDK2 inhibition enhances antitumor immunity by increasing IFN response to endogenous retroviruses","volume":"10","author":"Chen","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jim.2025.113904_bb0045","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1477-7819-11-118","article-title":"Nitric oxide and cancer: a review","volume":"11","author":"Choudhari","year":"2013","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.jim.2025.113904_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160096","article-title":"Tumor-preferential induction of immune responses and epidermal cell death in actinic Keratoses by Ingenol Mebutate","volume":"11","author":"Emmert","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jim.2025.113904_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/biom13060983","article-title":"Carcinogenesis and metastasis: focus on TRPV1-positive neurons and immune cells","volume":"13","author":"Erin","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.jim.2025.113904_bb0060","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jim.2025.113904_bb0065","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4049\/jimmunol.170.1.477","article-title":"Ablation of CD8 and CD4 T cell responses by high viral loads","volume":"170","author":"Fuller","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.jim.2025.113904_bb0070","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.4049\/jimmunol.172.7.4204","article-title":"Maintenance, loss, and resurgence of T cell responses during acute, protracted, and chronic viral infections","volume":"172","author":"Fuller","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.jim.2025.113904_bb0075","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jim.2025.113904_bb0080","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1146\/annurev.immunol.20.100301.064807","article-title":"Protein kinase C(theta) in T cell activation","volume":"20","author":"Isakov","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jim.2025.113904_bb0085","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2054758","article-title":"Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon \u00df-mediated suppression of immune checkpoint receptor expression","volume":"11","author":"Jeon","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jim.2025.113904_bb0090","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.4049\/jimmunol.2000612","article-title":"Dynamic roles for IL-2\u2013STAT5 signaling in effector and regulatory CD4+ T cell populations","volume":"205","author":"Jones","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.jim.2025.113904_bb0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.jim.2025.113904_bb0100","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood.2020008136","article-title":"Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma","volume":"139","author":"Karaca Atabay","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jim.2025.113904_bb0105","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/s41423-021-00712-w","article-title":"The two faces of IL-2: a key driver of CD8(+) T-cell exhaustion","volume":"18","author":"Kwon","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jim.2025.113904_bb0110","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1038\/s41467-023-40170-8","article-title":"A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity","volume":"14","author":"Liang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jim.2025.113904_bb0115","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrd3368","article-title":"Impact of high-throughput screening in biomedical research","volume":"10","author":"Macarron","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jim.2025.113904_bb0120","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1016\/j.celrep.2019.10.119","article-title":"Discovery of small molecules for the reversal of T cell exhaustion","volume":"29","author":"Marro","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.jim.2025.113904_bb0125","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","article-title":"The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells","volume":"42","author":"Martinez","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jim.2025.113904_bb0130","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.molimm.2004.04.015","article-title":"Protein tyrosine phosphatases in T cell physiology","volume":"41","author":"Mustelin","year":"2004","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jim.2025.113904_bb0135","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O\u2019Shea","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.jim.2025.113904_bb0140","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jim.2025.113904_bb0145","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jim.2025.113904_bb0150","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jim.2025.113904_bb0155","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1073\/pnas.1704227114","article-title":"Distinct PKC-mediated posttranscriptional events set cytokine production kinetics in CD8<sup>+<\/sup> T cells","volume":"114","author":"Salerno","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jim.2025.113904_bb0160","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jim.2025.113904_bb0165","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jim.2025.113904_bb0170","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jim.2025.113904_bb0175","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12531","article-title":"Introduction to checkpoint inhibitors and cancer immunotherapy","volume":"276","author":"Sharpe","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jim.2025.113904_bb0180","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1440-0960.2008.00497.x","article-title":"PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study","volume":"50","author":"Siller","year":"2009","journal-title":"Australas. J. Dermatol."},{"key":"10.1016\/j.jim.2025.113904_bb0185","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jim.2025.113904_bb0190","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8438172","article-title":"Intraluminal administration of resiniferatoxin protects against Clostridium difficile toxin A-induced colitis","volume":"2017","author":"Vigna","year":"2017","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.jim.2025.113904_bb0195","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1021\/acs.jnatprod.3c00811","article-title":"Sokotrasterol sulfate suppresses IFN-\u03b3-induced PD-L1 expression by inhibiting JAK activity","volume":"87","author":"Wang","year":"2024","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.jim.2025.113904_bb0200","article-title":"Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy","volume":"14","author":"Wei","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jim.2025.113904_bb0205","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jim.2025.113904_bb0210","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/JVI.77.8.4911-4927.2003","article-title":"Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment","volume":"77","author":"Wherry","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.jim.2025.113904_bb0215","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.jim.2025.113904_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109993","article-title":"Triptolide reduces PD-L1 through the EGFR and IFN-\u03b3\/IRF1 dual signaling pathways","volume":"118","author":"Xie","year":"2023","journal-title":"Int. Immunopharmacol."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175925001048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175925001048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:45:11Z","timestamp":1776833111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175925001048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":44,"alternative-id":["S0022175925001048"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2025.113904","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A high-throughput assay using dysfunctional T cells for phenotypic screening immune checkpoint modulators","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2025.113904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113904"}}